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Introduction: Based on many published reports, African American patients with cancer
experience higher pain severity scores and lower pain relief than White patients. This
disparity results from undertreatment of pain and is compounded by low adherence to
prescribed non-opioid and opioid analgesics among African American patients with cancer.
While nearly one in four patients use cannabis to manage cancer-related symptoms, less is
known about how cannabis use influences pain relief in this patient population.
Methods: This study is based on preliminary data from an ongoing study of longitudinal
outcomes of opioid therapy among African American and White patients with cancer. Linear
mixed-effects models were utilized to assess the interaction of race and cannabis use on pain
relief using “least pain” item scores from the Brief Pain Inventory (BPI) averaged across
three time points. Models were adjusted for sociodemographic and clinical variables.
Results: This analysis included 136 patients (49 African American, 87 White). Overall,
30.1% of the sample reported cannabis use for cancer pain. The mean “least pain” score on
BPI was 3.3 (SD=2.42) on a scale of 0–10. African American patients had a mean “least
pain” score 1.32±0.48 units higher (indicating lower pain relief) than White patients
(p=0.006). Cannabis use did not have a significant main effect (p=0.28). However, cannabis
use was a significant moderator of the relationship between race and “least pain” (p=0.03). In
the absence of cannabis use, African Americans reported higher “least pain” scores compared
to Whites (mean difference=1.631±0.5, p=0.001). However, this disparity was no longer
observed in African American patients reporting cannabis use (mean “least pain” differ
ence=0.587±0.59, p=0.32).
Conclusion: These findings point to the possible role of cannabis in cancer pain manage
ment and its potential to reduce racial disparities. These findings are preliminary and further
research into the role of cannabis in cancer pain outcomes is needed.
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Unrelieved pain is an issue of significant magnitude across the trajectory of cancer;
however, the burden is disproportionate for some groups. One of the most consis
tent findings on pain treatment disparities pertain to African Americans as identified
in key national reports1 and other systematic reviews.2,3 A meta-analysis synthesiz
ing 20 years of published research in the United States suggests that African
American patients have the highest risk of pain undertreatment than any other
racial and ethnic subgroup, regardless of the diagnosis.4 While both Whites and
African American patients report significant cancer-related pain across a number of
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studies,5–8 African American patients report a clinically
meaningful9 higher level of pain scores—an indicator of
inadequate pain relief. Stark disparities also have been
found between African Americans and Whites in their
use of prescribed non-opioid and opioid analgesics for
cancer pain.10 In one study, adherence to scheduled
opioids (ie, percentage of the total number of prescribed
doses taken) was only 57% for African Americans com
pared to 77% for Whites.8 Of note, African Americans
were 3 times more likely than Whites to show inconsistent
patterns of opioid adherence11 and appear to have unique
concerns related to use of analgesics. For instance, lower
household income, greater need for opioid information,
more severe side-effects, and poor communication with
providers predicted lower analgesic adherence for
African Americans, but not for Whites.8
Recent surveys report that nearly one in four cancer
patients use cannabis,12,13 and among those who use can
nabis, 75% use it to manage symptoms such as pain,
anxiety, and insomnia.14,15 Importantly, patients with can
cer also report using cannabis to avoid opioids, which
patients consider “harder medications” due to intolerable
side effects, stigma, and addiction concerns.16,17 The pur
pose of this brief report is to describe cannabis use in
a diverse sample of patients with cancer and to evaluate
whether cannabis use is associated with addressing racial
disparities in reported cancer pain relief.

Methods
This study concerns the analysis of preliminary data from
a larger, ongoing parent study (1R01NR017853) to eluci
date longitudinal outcomes of opioid therapy in patients
with cancer and how patterns of opioid use over time
relate to patient-reported outcomes and healthcare utiliza
tion. The data are based on a repeated measures survey
with patient-reported outcomes collected at 5 time points
(ie, T1= baseline; T2= 1 month; T3 = 2 months; T4= 3
months, T5 =5 months) combined with daily patientreported data through a smartphone-based application,
mobile Ecological Momentary Assessment (mEMA,
Ilumivu.com). Patients are recruited from outpatient med
ical oncology clinics of the University of Pennsylvania
Health System. Patients are included if they are ≥18
years of age, self-identify as African Americans or
Whites; are ambulatory patients with non-skin malignan
cies; and are prescribed opioids for pain (patients with
neuropathic pain are included). Patients are excluded if
they are receiving opioids only for treatment of an opioid
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use disorder (Medication for Opioid Use Disorder); are
prescribed opioids through non-oral routes (eg, intrave
nous, subcutaneous, rectal, transdermal, and transmucosal
routes); have any cognitive impairment or medical condi
tion that interfere with informed consent; or are residing in
a nursing home or receiving hospice care.
Potentially eligible patients are contacted by phone by
trained research staff who review the purpose of the study
using a standardized script. If a participant is interested, an
eligibility checklist is reviewed with the participant and
the trained staff answers any questions related to the study.
If the patient is eligible and remains interested, an appoint
ment is made based on patient’s convenience. Initially,
study staff made home visits to collect data to reduce
participant burden. However, due to the COVID-19 pan
demic, data collection has been transitioned to phonebased data collection, which has not posed any significant
difficulty with maintaining study procedures and rigor. The
informed consent form is reviewed prior to data collection
and all participants receive a copy of the form for their
records with the contact information of the study principal
investigator and study project manager. The study was
approved by the University of Pennsylvania’s
Institutional Review Board (IRB protocol # 833009).
This study was conducted in accordance with the
Declaration of Helsinki.

Study Measures
The cannabis use variable is obtained from two sources:
patients’ self-report during baseline study interview (T1),
as well as extracted from a review of patients’ electronic
medical records. In the self-reported interview, patients are
asked,
in the past week, have you used any of the following to
manage your pain? Please check all that apply. If you did
not use any of these therapies, then select none of the
above.

The response choices include medical cannabis, recrea
tional cannabis, and hemp-based cannabidiol (CBD) pro
ducts. Patients who reported the use of CBD products were
not included in the current analysis as “cannabis” users
because most CBD products are available as supplements
only, which have limited evidence for pain management
and there are currently no approved pharmaceutical grade
CBD-exclusive products for pain management.18
Pain is assessed using the Brief Pain Inventory (BPI)Short Form at each data collection time point. The BPI is
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comprised of two subscales assessing pain severity and
pain-related interference.19–21 The pain severity subscale
includes four items (“worst pain”, “least pain”, “average
pain”, and “pain now”) assessing different dimensions of
pain severity. The BPI “least pain” item was used due to
its clinical meaningfulness in assessing pain at its lowest
or degree of pain relief in an index period. The item asks,
“please rate your pain by circling the one number that best
describes your pain “at its least” in the last 24 hours,” and
is scored on a scale of 0–10 (0=no pain and 10=pain as bad
as you can imagine). A higher “least pain” score indicates
lower pain relief. The psychometric properties of the BPI
are well established with cancer patients with a Cronbach’s
alpha that ranges from 0.77 to 0.91.19,20 The validity and
reliability of single recall-based “least pain” items for pain
intensity have been demonstrated in the cancer
population.22
Analgesic side-effects are assessed using the
Medication Side-effects Checklist (MSEC). MSEC elicits
information on the presence and severity of eight common
analgesic side-effects (ie, constipation, drowsiness, nau
sea, vomiting, confusion, dry mouth, stomach irritation,
itching) on a scale of 0–10 (no severity-extreme severity).
The internal consistency reliability is 0.80.23
The Pain Self-Efficacy Questionnaire (PSEQ)24 is used
to assess confidence in performing activities while in pain
(household chores, socializing, work, coping with pain
without medications). The internal consistency reliability
for this tool ranges 0.81–0.92.24
We also used the Current Opioid Misuse Measure
(COMM),25 a 17-item tool, to assess behaviors that con
textualize current opioid misuse events with a cut-off of ≥9
suggesting opioid misuse. The internal consistency relia
bility for this tool ranges 0.81–0.86.25

Data Analysis
The present analysis includes the first 136 patients enrolled
in the ongoing study. The data presented here are from
three time points (T1-T3) from the ongoing parent study.
Summary statistics were computed for the 136 patients
included in this analysis and stratified by race for partici
pants’ baseline clinical and demographic characteristics
using means and standard deviations for continuous mea
sures, and frequencies and percentages for categorical
measures. Clinical and demographic characteristics were
compared between race groups using chi-squared and oneway ANOVA for categorical and continuous measures,
respectively. Distribution of the outcome measure was
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assessed using histograms and tested for normality using
Shapiro–Wilk tests and Kolmogorov–Smirnov tests.
Linear mixed-effects models were produced to assess
the effects of race and cannabis use on participants’ least
pain (ie, time-averaged BPI “least pain” scores at three
time points). Cannabis use was then assessed as
a moderator of the relationship between race and “least
pain” by testing the cannabis use by race interaction term.
An unstructured covariance matrix was used to account for
within-subject variance in pain outcomes. All models were
adjusted for the effects of participant age, gender, income,
insurance status, cancer stage, cancer treatment status
(active treatment or completed cancer treatment), pre
scribed morphine milligram equivalent per day (MME/
day), opioid prescription type (long-acting only, immedi
ate-release opioid only; or both), current opioid misuse
measure (COMM score), medication side-effects (MSCE
score), pain self-efficacy (PSEQ score). Statistical analysis
was conducted using SAS 9.4 for Windows.

Results
Tables 1 and 2 summarize the sociodemographic and ill
ness-related characteristics of the sample by their selfidentified race. The present analysis included 136 patients
(n=87 Whites [64%]; n=49 African Americans [36%]),
who were largely older adult (M=60.9 years; SD=11.79),
and females (75%) with low annual household incomes of
less than $30,000 (43%). Cancers were typically (46.3%)
advanced (Stage III/IV), and breast (27.9%) and lung
(10.3%) cancer were most common. Most opioid prescrip
tions (50.4%) included combined long- and short-acting
formulations, with high MME/day: MME/day (30.9%) and
≥90 /day (30.9%) and >90 MME/day (29.4%). The mean
“least pain” score was 3.3 (SD=2.42) overall, where the
average “least pain” score by group was lower among
Whites (M=2.5, SD=2.1) than African Americans
(M=4.7, SD=2.32). At baseline, 41 patients (30.1%)
reported cannabis use, with the majority of these patients
reporting medical cannabis (Table 3).
Race was found to be a significant predictor of “least
pain” in the adjusted longitudinal analysis. Specifically,
African American participants were estimated to have
a mean “least pain” score 1.32±0.48 units higher (ie,
indicating lower pain relief) than White participants
(p=0.006). Cannabis use was not found to exhibit
a significant main effect on “least pain” (p=0.28).
However, in assessing cannabis use as a moderator of
the relationship between race and “least pain”, the
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Table 1 Sociodemographic Characteristics by Participant Race
Participant

Total (N=136)

Characteristics
Gender

Female

Journal of Pain Research downloaded from https://www.dovepress.com/ by 76.99.118.70 on 04-Dec-2021
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p-value

0.100

34 (25.0%)

8 (16.3%)

26 (29.9%)

102 (75.0%)

41 (83.7%)

61 (70.1%)

N

136

49

87

Mean

60.9

60.0

61.4

SD
Min

11.79
26.0

11.91
34.0

11.75
26.0

Max

84

84

84

No

122 (89.7%)

40 (81.6%)

82 (94.3%)

Yes

14 (10.3%)

9 (18.4%)

5 (5.7%)

134 (98.5%)

49 (100.0%)

85 (97.7%)

Married

62 (45.6%)

10 (20.4%)

52 (59.8%)

Separated Divorced
Widowed

40 (29.4%)

16 (32.7%)

24 (27.6%)

Never Married

34 (25.0%)

23 (46.9%)

11 (12.6%)

High School (09–12) or less

65 (47.8%)

33 (67.3%)

32 (36.8%)

College/trade School (13–16)

45 (33.1%)

16 (32.7%)

29 (33.3%)

More than college (>17)

26 (19.1%)

< $30,000

58 (42.6%)

41 (83.7%)

17 (19.5%)

$30,000-$89,999
≥$90,000

43 (31.6%)
35 (25.7%)

8 (16.3%)

35 (40.2%)
35 (40.2%)

Employed
Unemployed/Disabled/Other

20 (16.0%)
59 (47.2%)

2 (4.5%)
27 (61.4%)

18 (22.2%)
32 (39.5%)

Retired

46 (36.8%)

15 (34.1%)

31 (38.3%)

No

65 (47.8%)

38 (77.6%)

27 (31.0%)

Yes

71 (52.2%)

11 (22.4%)

60 (69.0%)

No

96 (70.6%)

20 (40.8%)

76 (87.4%)

Yes

40 (29.4%)

29 (59.2%)

11 (12.6%)

No

68 (50.0%)

26 (53.1%)

42 (48.3%)

Yes

68 (50.0%)

23 (46.9%)

45 (51.7%)

VA Insurance

No

136 (100.0%)

49 (100.0%)

87 (100.0%)

Other Insurance

No
Yes

126 (92.6%)
10 (7.4%)

49 (100.0%)

77 (88.5%)
10 (11.5%)

Multiracial

Ethnicity

Hispanic or Latino
Non-Hispanic

Marital Status

Education

Household Income

Employment Status

Private Insurance

Medicaid

Medicare

2 (1.5%)

interaction term between race and cannabis was found to
be statistically significant (p=0.03). Pairwise (across time
and including baseline) comparisons of time-averaged
model-based means (Table 4) indicated that a significant
racial disparity in pain relief exists among those who did
not use cannabis such that African American patients
reported higher “least pain” scores (indicating lower pain
relief) compared to White patients (mean difference=1.631
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(n=49)
Male

Age
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2 (2.3%)

0.504

0.036

0.536

0.000

0.000

26 (29.9%)
0.000

0.011

0.000

0.000

0.721

0.014

±0.5, p=0.001; Figure 1). However, this disparity was no
longer evident among those who used cannabis (mean
difference=0.587±0.59, p=0.32). We also conducted
a sensitivity analysis in which we adjusted for other sub
stance use. We did not find other substance use to signifi
cantly predict pain relief (p=0.3397) and found the
interaction between race and cannabis use to remain sta
tistically significant (p=0.0347).
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Table 2 Illness and Pain Characteristics by Participant Race
Participant

Total (N=136)

Characteristics
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BPI Least Pain

BPI Worst Pain

BPI Average Pain

BPI Now Pain

BPI Severity

BPI Interference

Cancer Type

Opioid Prescription
Group

MME Category

White (n=87)

p-value

0.000

(n=49)
N

136

49

87

Mean

3.3

4.7

2.5

SD
Min

2.42
0.0

2.32
0.0

2.10
0.0

Max

10

10

9

N

136

49

87

Mean
STD

6.7
2.34

8.0
1.66

5.9
2.33

Min

0.0

3.0

0.0

Max

10

10

10

N

135

49

86

Mean
STD

5.1
2.22

6.5
1.79

4.3
2.03

Min

0.0

3.0

0.0

Max

10

10

10

N

136

49

87

Mean
STD

4.1
2.81

5.4
2.89

3.3
2.46

Min

0.0

0.0

0.0

Max

10

10

9

N

136

49

87

Mean
STD

4.8
2.17

6.2
1.82

4.0
1.95

Min

0.0

2.5

0.0

Max

10

10

9

N

136

49

87

Mean
STD

4.9
2.66

5.9
2.73

4.4
2.48

Min

0.0

0.0

0.0

Max

10

10

9

Lung

14 (10.3%)

7 (14.3%)

7 (8.0%)

Breast
Colon

38 (27.9%)
5 (3.7%)

16 (32.7%)
2 (4.1%)

22 (25.3%)
3 (3.4%)

Prostate

Cancer Stage

African American

5 (3.7%)

2 (4.1%)

3 (3.4%)

Other

74 (54.4%)

22 (44.9%)

52 (59.8%)

I/II

44 (32.4%)

16 (32.7%)

28 (32.2%)

III/IV
Unknown/In Situ

63 (46.3%)
29 (21.3%)

20 (40.8%)
13 (26.5%)

43 (49.4%)
16 (18.4%)

SA/PRN Only
LA/ATC Only

49 (36.3%)
18 (13.3%)

25 (52.1%)
1 (2.1%)

24 (27.6%)
17 (19.5%)

Both SA/PRN and LA/ATC

68 (50.4%)

22 (45.8%)

46 (52.9%)

<=25 MME

24 (17.6%)

12 (24.5%)

12 (13.8%)

26–50 MME
51–90 MME

30 (22.1%)
42 (30.9%)

10 (20.4%)
15 (30.6%)

20 (23.0%)
27 (31.0%)

90+ MME

40 (29.4%)

12 (24.5%)

28 (32.2%)

0.000

0.000

0.000

0.000

0.002

0.491

0.470

0.001

0.444

(Continued)
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Table 2 (Continued).
Participant

Total (N=136)

Characteristics
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For personal use only.

COMM Score

White (n=87)

p-value

0.333

(n=49)
N

136

49

87

Mean
SD

6.2
4.71

5.7
4.39

6.5
4.88

Min

0.0

0.0

0.0

Max

20

16

20

History of Other

None

45 (33.1%)

8 (16.3%)

37 (42.5%)

Substance Use

Alcohol
Tobacco

12 (8.8%)
35 (25.7%)

3 (6.1%)
14 (28.6%)

9 (10.3%)
21 (24.1%)

PSEQ Score

Cocaine

4 (2.9%)

4 (8.2%)

-

Illicit Cannabis

1 (0.7%)

1 (2.0%)

-

N

136

49

87

32.9
14.97

29.5
17.06

34.9
13.38

Min

0.0

0.0

1.0

Max

60

60

60

Mean
SD

MSCE Score

0.001

0.044

N

136

49

87

Mean
SD

1.9
1.53

2.2
1.87

1.7
1.29

Min

0.0

0.0

0.0

Max

7

7

6

No

122 (89.7%)

48 (98.0%)

74 (85.1%)

Yes

14 (10.3%)

1 (2.0%)

13 (14.9%)

Cognitive Behavioral
Therapy

No
Yes

132 (97.1%)
4 (2.9%)

47 (95.9%)
2 (4.1%)

85 (97.7%)
2 (2.3%)

0.619

Physical Therapy

No
Yes

35 (25.9%)
100 (74.1%)

8 (16.7%)
40 (83.3%)

27 (31.0%)
60 (69.0%)

0.100

Occupational
Therapy

No
Yes

71 (52.6%)
64 (47.4%)

20 (41.7%)
28 (58.3%)

51 (58.6%)
36 (41.4%)

0.072

Acupuncture

0.127

0.018

Abbreviations: BPI, Brief Pain Inventory; ATC, around-the-clock; LA, long-acting; PRN, as needed; SA, short acting; MME/day, prescribed morphine milligram equivalent
per day; COMM, current opioid misuse measure; MSCE, medication side-effects checklist; PSEQ, Pain Self-Efficacy Questionnaire.

Discussion
In this preliminary analysis of a larger, ongoing parent study
of the longitudinal outcomes of opioid therapy among
patients with cancer, we evaluated whether cannabis moder
ates the relationship between race and pain outcomes. Our
primary finding is that cannabis may reduce racial disparities
in pain relief in this population. Although this finding should
be considered preliminary, it highlights the growing need to
better understand the role of cannabis in cancer pain manage
ment, particularly as it relates to racial disparities.
Indeed, we found that among patients with cancer who did
not report cannabis use, there was a significant disparity in
adequate pain relief between African American and White
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patients, with African American patients reporting signifi
cantly higher “least pain” scores compared to White patients.
This finding is consistent with a large body of evidence
demonstrating that African Americans experience inadequate
pain relief, relative to White patients.4,7,26,27 These relatively
high “least pain” scores are also particularly striking consider
ing that 60% of the sample were prescribed over 50 MME/day
of opioids. Adding to the literature, our data suggest that this
disparity is significantly reduced among patients who report
cannabis use. Given the well-established disparities in the
prescribing of analgesics and in particular opioids for cancer
pain among African American and White patients, this finding
warrants additional research to better understand the
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Table 3 Reported Cannabis Use by Participant Race
Participant

Total (N=136)

African American

Characteristics
Cannabis Use

Journal of Pain Research downloaded from https://www.dovepress.com/ by 76.99.118.70 on 04-Dec-2021
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Cannabis Source

p-value

0.245

No

95 (69.9%)

31 (63.3%)

64 (73.6%)

Yes

41 (30.1%)

18 (36.7%)

23 (26.4%)

No Cannabis

95 (69.9%)

31 (63.3%)

64 (73.6%)

Recreational

6 (4.4%)

2 (4.1%)

4 (4.6%)

33 (24.3%)
2 (1.5%)

14 (28.6%)
2 (4.1%)

19 (21.8%)

No

122 (89.7%)

46 (93.9%)

76 (87.4%)

Yes

14 (10.3%)

3 (6.1%)

11 (12.6%)

Medical
Medical and Recreational
CBD Use

White (n=87)

(n=49)

0.221

0.378

Table 4 Model-Based Least Pain Score Means for the Interaction Model
Race

Adjusteda

Unadjusted
Cannabis Use

Estimate

Standard Error

Estimate

Standard Error

African American

Yes

3.6862

0.3648

3.3312

0.4567

African American
White

No
Yes

4.3355
2.6396

0.3093
0.3563

4.1254
2.7447

0.425
0.4053

White

No

2.1447

0.2483

2.4947

0.3037

Notes: aAdjusted for the effects of participant age, gender, income, insurance status, cancer stage, cancer treatment status (active treatment or completed cancer
treatment), opioid prescription type (long-acting only, immediate-release opioid only; or both).
Abbreviations: MME/day, prescribed morphine milligram equivalent per day; COMM score, current opioid misuse measure; MSCE score, medication side-effects; PSEQ
score, pain self-efficacy.

influences of cannabis use on opioid access, opioid use, pain
relief, and racial differences.
Consistent with recent surveys,12,13,28 approximately 30%
of the current sample reported using cannabis. Although the
majority of these patients reported using medical cannabis,
several patients reported using recreational cannabis or
a combination of medical and recreational cannabis. Patients
concerned about stigma29 may be reluctant to disclose canna
bis use and thus, these findings may be an underrepresentation

Figure 1 Interaction effects of cannabis on race and pain relief.

Journal of Pain Research 2021:14

of cannabis use. Potential racial differences in perceived risk
of cannabis use such that African Americans report higher
perceived risk than Whites30 may have contributed to under
reporting of use in this sample. Although the prior study did
not differentiate between perceived risk associated with
recreational purposes versus medical reasons, the current
data provide insight into the role of cannabis in cancer pain
management when considered in the context of race.
In contrast to some previous studies,14,15 we did not find an
overall main effect of cannabis use on pain. This could be due
in part to the fact that the current study was focused on opioid
adherence profiles and future studies would benefit from
a more granular and longitudinal assessment of cannabis use
as it relates to self-reported pain and opioid use. Additionally,
increased focus on form (inhaled, oral, topical) and frequency
of cannabis use in real time is necessary to better clarify and
understand the interaction between cancer pain, opioid use,
and pain outcomes. While cannabis use is common, there
continues to be a lack of comfort in conversation between
patient and clinician around use, often leading to illicit (ie,
recreational) rather than state-regulated access to medical
cannabis.31 This is important as medical cannabis is purer
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and there are formulations that provide greater analgesia
which is not necessarily the case in recreational cannabis.
Also, vaping or smoking cannabis can be carcinogenic. An
open, nonjudgmental discussion between the clinician and the
patient can maximize the potential efficacy of cannabis and
mitigate risks. For us to understand the true breadth and impact
of cannabis use on patients with cancer, knowing the limita
tions in communication and lack of standard legal approach
and availability of cannabis state by state, we need to examine
both licit and illicit cannabis use to tell the full story.

Limitations
Our study is based on data from a single health system. The
aims presented here do not reflect the original aims of the
funded grant and represent emergent findings. Thus, these
findings are preliminary, hypothesis-generating, and subject
to change based on additional data that are being collected
or studies designed specifically to investigate these aims.
The cannabis data are based on patient’s self-report, which
currently represents the best source of data, as the use of
cannabis is not reliably collected in patients’ medical
records. The analysis does not account for frequency,
route, and source (medical vs recreational cannabis) as the
data are not reliably available. Patients may use recreational
cannabis for medical reasons and frequently transition
between medical and recreational sources based on cost
and availability. Also, we did not include patients receiving
CBD in this analysis given the significant variation in overthe-counter (ie, supplemental) CBD products, which have
limited evidence for pain management.17,32 Further, while
the developers of the BPI survey recommend that all four
pain severity items be employed,20 they also acknowledge
use of single BPI items,20 which is supported by the
Initiative on Methods, Measurement, and Pain Assessment
in Clinical Trials (IMMPACT) recommendations for

assessing pain in pain studies and clinical trials33–35 and
by other industry standards.36 However, we acknowledge
that despite the validity and reliability of the BPI “least
pain” item,21 it is a unidimensional report of pain severity
limiting our understanding of the other dimensions of pain
severity and whether or not the reported “least pain” scores
were actually tolerable pain levels for the patients.37
We did not intentionally analyze least pain scores, but
it was an incidental finding that we tested further. While
we did not detect statistical significance (alpha set at 0.05)
of the race by cannabis interaction for other BPI pain items
(pain worst, pain now, pain average), we did observe
consistent trends in the direction of effects for BPI worst
pain, BPI pain severity subscale, and BPI pain interference
subscale, which strengthens confidence in the preliminary
results (Table 5). The effect size estimates presented may
be useful to researchers who may need effect size data to
compute sample sizes for future studies.
While our study adjusted for daily morphine milligram
equivalent as a covariate in the analysis presented, due to
limitations of our current sample size, we did not assess com
plex interactions that included daily or oral morphine equiva
lent as an additional moderator of associations between race,
cannabis use, and pain outcomes and recommend that future
studies investigate the relationship with opioid daily dose.

Conclusions
These preliminary findings point to an important role of
cannabis use in cancer pain and its potential to reduce racial
disparities in cancer pain management, which is a significant
clinical issue. Future studies are needed to study the role of
cannabis more rigorously in cancer pain outcomes, including
investigating its role in closing racial disparities. Studies are
also needed to understand the role of medical vs recreational
sources of cannabis in these outcomes.

Table 5 Effect Size Estimates for Race×Cannabis Use Interaction for BPI Outcomesa
Outcome
BPI Least Pain
BPI Now Pain

Estimate

Standard Error

Cohen’s D

df

t Value

Pr > |t|

−1.0442
0.6713

0.4854
0.6209

0.43139
0.22844

124
124

−2.15
1.08

0.0334
0.2817

−0.5007

0.5454

0.18532

124

−0.92

0.3603

BPI Average Pain
BPI Severity Subscale

−0.07339
−0.08274

0.4649
0.4439

0.02961
0.03458

123
124

−0.16
−0.19

0.8748
0.8524

BPI Interference Subscale

−0.06163

0.4978

0.02193

124

−0.12

0.9017

BPI Worst Pain

a

Notes: Adjusted for the effects of participant age, gender, income, insurance status, cancer stage, cancer treatment status (active treatment or completed cancer
treatment), opioid prescription type (long-acting only, immediate-release opioid only; or both).
Abbreviations: BPI, Brief Pain Inventory; MME/day, prescribed morphine milligram equivalent per day; COMM score, current opioid misuse measure; MSCE score,
medication side-effects; PSEQ score, pain self-efficacy.
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